Bachem has signed a new framework agreement to provide large volumes of peptides to an unnamed customer following a joint development project. This covers “a committed volume at an equivalent value of over CHF 500 million for the five-year period of 2027-2031, with significant upside potential,” the company said.

This follows recent deals a previous large-volume contract for another unnamed customer worth CHF 175 million in 2023-4. The deal was announced in September 2022 and subsequently upgraded with a further work order for a minimum total of CHF 1 billion from 2025 to 2029.

Peptides giant Bachem has agreed to acquire an undeveloped site covering 155,000 m² in Sisslerfeld, north-western Switzerland, from DSM in order to manage growing demand. It has already acquired the first plot and others will follow in time. Terms are not being disclosed.